Compared with ESAs, PHIs, as HIF stabilizers, demonstrated good effectiveness in treating CKD-related anemia with a comprehensive effect on replenishing endogenous EPO, decreasing hepcidin, and improving the bioavailability of iron. The gene discussed is HAMP; the disease is chronic kidney disease.